Compare Dishman Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. REDDYS LAB - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. REDDYS LAB DISHMAN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 21.6 115.9% View Chart
P/BV x 3.3 3.2 103.3% View Chart
Dividend Yield % 0.7 0.7 91.1%  

Financials

 DISHMAN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. REDDYS LAB
Mar-19
DISHMAN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3742,875 13.0%   
Low Rs1291,888 6.8%   
Sales per share (Unadj.) Rs197.8930.2 21.3%  
Earnings per share (Unadj.) Rs21.2117.4 18.1%  
Cash flow per share (Unadj.) Rs34.7185.8 18.7%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.8 94.6%  
Book value per share (Unadj.) Rs179.9844.4 21.3%  
Shares outstanding (eoy) m80.69166.07 48.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.6 49.7%   
Avg P/E ratio x11.920.3 58.5%  
P/CF ratio (eoy) x7.212.8 56.5%  
Price / Book Value ratio x1.42.8 49.6%  
Dividend payout %9.417.0 55.4%   
Avg Mkt Cap Rs m20,306395,496 5.1%   
No. of employees `0000.822.0 3.8%   
Total wages/salary Rs m5,35533,562 16.0%   
Avg. sales/employee Rs Th19,252.77,032.8 273.8%   
Avg. wages/employee Rs Th6,459.51,527.9 422.8%   
Avg. net profit/employee Rs Th2,064.1887.7 232.5%   
INCOME DATA
Net Sales Rs m15,961154,482 10.3%  
Other income Rs m2653,375 7.9%   
Total revenues Rs m16,226157,857 10.3%   
Gross profit Rs m4,10331,782 12.9%  
Depreciation Rs m1,09111,348 9.6%   
Interest Rs m944889 106.2%   
Profit before tax Rs m2,33422,920 10.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m1438 0.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,858 16.2%   
Profit after tax Rs m1,71119,500 8.8%  
Gross profit margin %25.720.6 125.0%  
Effective tax rate %26.716.8 158.8%   
Net profit margin %10.712.6 84.9%  
BALANCE SHEET DATA
Current assets Rs m11,018111,101 9.9%   
Current liabilities Rs m9,51758,973 16.1%   
Net working cap to sales %9.433.7 27.9%  
Current ratio x1.21.9 61.5%  
Inventory Days Days11079 139.3%  
Debtors Days Days3594 37.0%  
Net fixed assets Rs m16,304101,245 16.1%   
Share capital Rs m161830 19.4%   
"Free" reserves Rs m12,907139,406 9.3%   
Net worth Rs m14,516140,236 10.4%   
Long term debt Rs m4,18922,000 19.0%   
Total assets Rs m29,805224,656 13.3%  
Interest coverage x3.526.8 13.0%   
Debt to equity ratio x0.30.2 184.0%  
Sales to assets ratio x0.50.7 77.9%   
Return on assets %8.99.1 98.2%  
Return on equity %11.813.9 84.8%  
Return on capital %17.514.9 117.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95288,673 5.6%   
Fx outflow Rs m69719,104 3.6%   
Net fx Rs m4,25569,569 6.1%   
CASH FLOW
From Operations Rs m2,78628,704 9.7%  
From Investments Rs m-1,529-7,727 19.8%  
From Financial Activity Rs m-941-21,326 4.4%  
Net Cashflow Rs m316-314 -100.8%  

Share Holding

Indian Promoters % 61.4 25.5 240.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.4 68.5%  
FIIs % 12.7 35.3 36.0%  
ADR/GDR % 0.0 18.5 -  
Free float % 22.1 15.3 144.4%  
Shareholders   46,261 75,885 61.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS